Precision Wealth Strategies LLC Purchases Shares of 62,042 Aurinia Pharmaceuticals Inc $AUPH

Precision Wealth Strategies LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 62,042 shares of the biotechnology company’s stock, valued at approximately $686,000.

Other institutional investors also recently made changes to their positions in the company. Hussman Strategic Advisors Inc. boosted its position in Aurinia Pharmaceuticals by 70.0% during the second quarter. Hussman Strategic Advisors Inc. now owns 357,000 shares of the biotechnology company’s stock valued at $3,024,000 after buying an additional 147,000 shares during the period. Strs Ohio bought a new stake in shares of Aurinia Pharmaceuticals in the 1st quarter valued at about $636,000. Public Employees Retirement System of Ohio purchased a new stake in Aurinia Pharmaceuticals during the 2nd quarter valued at about $282,000. Marex Group plc bought a new position in Aurinia Pharmaceuticals during the 2nd quarter worth approximately $1,143,000. Finally, Acropolis Investment Management LLC bought a new stake in Aurinia Pharmaceuticals in the second quarter valued at approximately $242,000. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Down 1.9%

NASDAQ AUPH opened at $15.90 on Friday. The company has a quick ratio of 5.17, a current ratio of 5.76 and a debt-to-equity ratio of 0.15. Aurinia Pharmaceuticals Inc has a twelve month low of $6.55 and a twelve month high of $16.54. The firm has a market capitalization of $2.10 billion, a PE ratio of 28.39 and a beta of 1.42. The stock’s 50 day moving average is $14.77 and its 200 day moving average is $11.97.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.16 by $0.07. The company had revenue of $73.47 million during the quarter, compared to analyst estimates of $67.70 million. Aurinia Pharmaceuticals had a net margin of 29.28% and a return on equity of 25.19%. Research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on AUPH. Leerink Partners lowered Aurinia Pharmaceuticals from an “outperform” rating to a “market perform” rating and increased their price objective for the company from $15.00 to $16.00 in a research note on Wednesday, December 3rd. Bloom Burton cut shares of Aurinia Pharmaceuticals from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings reissued a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $15.00 price objective (up from $9.00) on shares of Aurinia Pharmaceuticals in a research note on Wednesday, November 5th. Finally, Jefferies Financial Group upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and increased their target price for the stock from $10.00 to $21.00 in a report on Friday, November 7th. Two research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Aurinia Pharmaceuticals has an average rating of “Hold” and an average target price of $17.25.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.